A study involving 126 individuals diagnosed with NASH found that the daily intake of 20 mg firsocostat, an inhibitor of ACC, resulted in a significant decrease of 29% in the amount of fat in the liver (Alkhouri et al., 2020). This evidence concerns the gene ACACA and metabolic dysfunction-associated steatohepatitis.